Cancer Research Technology and University of Cambridge Spin-out Company, Chroma Therapeutics, Announces Completion of $53m Series C Financing
London, UK, 3 April 2006 - Chroma Therapeutics Ltd, a UK based biotechnology company focused on small molecule cancer and inflammation therapeutics, announces it has completed a $53 million (£30 million) Series C financing round. The round was led by Nomura Phase4 Ventures, a leading international healthcare investor based in London. Chroma will use the funds to develop its lead program, CHR-2797, through Phase 2 clinical studies and to move its HDAC and aurora kinase inhibitor programs into clinical development.
To view the original press release on the Chroma Therapeutics website click here.
|
